This article, entitled “QGC606, a best-in-class orally active centrally acting aminopeptidase A inhibitor prodrug, for treating heart failure following myocardial infarction,” presents the results of a study conducted with QGC606 in mice following myocardial infarction, in collaboration with the INSERM team led by Catherine Llorens-Cortes at the Collège de France and the team at the…
